TW202202146A - 用於治療呼吸病況之ｇａｂａａ調節劑之用途 - Google Patents
用於治療呼吸病況之ｇａｂａａ調節劑之用途 Download PDFInfo
- Publication number
- TW202202146A TW202202146A TW110110914A TW110110914A TW202202146A TW 202202146 A TW202202146 A TW 202202146A TW 110110914 A TW110110914 A TW 110110914A TW 110110914 A TW110110914 A TW 110110914A TW 202202146 A TW202202146 A TW 202202146A
- Authority
- TW
- Taiwan
- Prior art keywords
- hour
- administered
- gaba
- pam
- compound
- Prior art date
Links
- 230000000241 respiratory effect Effects 0.000 title claims abstract description 47
- 238000011282 treatment Methods 0.000 title claims description 135
- 208000024891 symptom Diseases 0.000 claims abstract description 62
- 229940125904 compound 1 Drugs 0.000 claims description 224
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 190
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 190
- 150000003839 salts Chemical class 0.000 claims description 182
- 229940126027 positive allosteric modulator Drugs 0.000 claims description 181
- 238000001802 infusion Methods 0.000 claims description 129
- SFXPZLCQRZASKK-UHFFFAOYSA-N (3alpha,5alpha)-3-Hydroxypregn-16-en-20-one Natural products C1CC2CC(O)CCC2(C)C2C1C1CC=C(C(=O)C)C1(C)CC2 SFXPZLCQRZASKK-UHFFFAOYSA-N 0.000 claims description 110
- SFXPZLCQRZASKK-CKBUFISISA-N 1-[(3s,5s,8r,9s,10s,13s,14s)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl]ethanone Chemical group C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC=C(C(=O)C)[C@@]2(C)CC1 SFXPZLCQRZASKK-CKBUFISISA-N 0.000 claims description 110
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 84
- 150000001875 compounds Chemical class 0.000 claims description 82
- 201000010099 disease Diseases 0.000 claims description 75
- 229910052760 oxygen Inorganic materials 0.000 claims description 75
- 239000001301 oxygen Substances 0.000 claims description 74
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 70
- 239000003795 chemical substances by application Substances 0.000 claims description 61
- 206010061218 Inflammation Diseases 0.000 claims description 58
- 230000004054 inflammatory process Effects 0.000 claims description 58
- 241000711573 Coronaviridae Species 0.000 claims description 56
- 230000002685 pulmonary effect Effects 0.000 claims description 43
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 40
- 206010035664 Pneumonia Diseases 0.000 claims description 38
- 208000025721 COVID-19 Diseases 0.000 claims description 37
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 35
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 35
- 210000004072 lung Anatomy 0.000 claims description 35
- 238000001990 intravenous administration Methods 0.000 claims description 33
- -1 antibodies Substances 0.000 claims description 32
- 208000015181 infectious disease Diseases 0.000 claims description 32
- 210000001519 tissue Anatomy 0.000 claims description 30
- 241000282414 Homo sapiens Species 0.000 claims description 29
- 241000700605 Viruses Species 0.000 claims description 27
- 238000002560 therapeutic procedure Methods 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 23
- 210000004369 blood Anatomy 0.000 claims description 19
- 239000008280 blood Substances 0.000 claims description 19
- 206010016654 Fibrosis Diseases 0.000 claims description 17
- 230000004761 fibrosis Effects 0.000 claims description 17
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims description 16
- 230000036407 pain Effects 0.000 claims description 16
- 241001678559 COVID-19 virus Species 0.000 claims description 15
- 206010038687 Respiratory distress Diseases 0.000 claims description 15
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 14
- 230000036783 anaphylactic response Effects 0.000 claims description 14
- 208000003455 anaphylaxis Diseases 0.000 claims description 14
- 208000006673 asthma Diseases 0.000 claims description 14
- 201000010064 diabetes insipidus Diseases 0.000 claims description 14
- 208000023504 respiratory system disease Diseases 0.000 claims description 13
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 12
- 108010063738 Interleukins Proteins 0.000 claims description 12
- 102000015696 Interleukins Human genes 0.000 claims description 12
- AURFZBICLPNKBZ-UHFFFAOYSA-N Pregnanolone Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 AURFZBICLPNKBZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000003242 anti bacterial agent Substances 0.000 claims description 12
- 239000003443 antiviral agent Substances 0.000 claims description 12
- 208000035143 Bacterial infection Diseases 0.000 claims description 11
- 241000315672 SARS coronavirus Species 0.000 claims description 11
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 11
- 206010006451 bronchitis Diseases 0.000 claims description 11
- 230000007547 defect Effects 0.000 claims description 11
- SJMMDWXJSSJHOQ-UHFFFAOYSA-N 5-fluoro-2-[2-fluoro-5-[8-fluoro-7-(2-hydroxypropan-2-yl)imidazo[1,2-a]pyridin-3-yl]phenyl]benzonitrile Chemical compound C=1N=C2C(F)=C(C(C)(O)C)C=CN2C=1C(C=1)=CC=C(F)C=1C1=CC=C(F)C=C1C#N SJMMDWXJSSJHOQ-UHFFFAOYSA-N 0.000 claims description 10
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 claims description 10
- PGTVWKLGGCQMBR-FLBATMFCSA-N Ganaxolone Chemical compound C([C@@H]1CC2)[C@](C)(O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 PGTVWKLGGCQMBR-FLBATMFCSA-N 0.000 claims description 10
- 208000036142 Viral infection Diseases 0.000 claims description 10
- 229950004346 gaboxadol Drugs 0.000 claims description 10
- 229950006567 ganaxolone Drugs 0.000 claims description 10
- YRMLUAGKHYADKJ-UHFFFAOYSA-N necopidem Chemical compound C1=CC(CC)=CC=C1C1=C(CN(C)C(=O)CC(C)C)N2C=C(C)C=CC2=N1 YRMLUAGKHYADKJ-UHFFFAOYSA-N 0.000 claims description 10
- 229950002306 necopidem Drugs 0.000 claims description 10
- 230000009385 viral infection Effects 0.000 claims description 10
- NZMJFRXKGUCYNP-UHFFFAOYSA-N α5ia Chemical compound O1C(C)=CC(C=2N3N=C(OCC=4N=NN(C)C=4)C4=CC=CC=C4C3=NN=2)=N1 NZMJFRXKGUCYNP-UHFFFAOYSA-N 0.000 claims description 10
- 208000025370 Middle East respiratory syndrome Diseases 0.000 claims description 9
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 9
- 241000191967 Staphylococcus aureus Species 0.000 claims description 9
- 208000009470 Ventilator-Associated Pneumonia Diseases 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- 238000012545 processing Methods 0.000 claims description 9
- 208000011580 syndromic disease Diseases 0.000 claims description 9
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 8
- 206010033645 Pancreatitis Diseases 0.000 claims description 8
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 8
- 239000002249 anxiolytic agent Substances 0.000 claims description 8
- 210000003205 muscle Anatomy 0.000 claims description 8
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims description 8
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 claims description 7
- 241000150452 Orthohantavirus Species 0.000 claims description 7
- 206010003694 Atrophy Diseases 0.000 claims description 6
- 241000430519 Human rhinovirus sp. Species 0.000 claims description 6
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 6
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 6
- 230000037444 atrophy Effects 0.000 claims description 6
- 201000009267 bronchiectasis Diseases 0.000 claims description 6
- 238000002106 pulse oximetry Methods 0.000 claims description 6
- 241000712461 unidentified influenza virus Species 0.000 claims description 6
- 241001647372 Chlamydia pneumoniae Species 0.000 claims description 5
- 206010013883 Dwarfism Diseases 0.000 claims description 5
- 241000606768 Haemophilus influenzae Species 0.000 claims description 5
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims description 5
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 5
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 5
- 230000007812 deficiency Effects 0.000 claims description 5
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 5
- 238000007918 intramuscular administration Methods 0.000 claims description 5
- 229960003085 meticillin Drugs 0.000 claims description 5
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 5
- 238000007920 subcutaneous administration Methods 0.000 claims description 5
- 102100034452 Alternative prion protein Human genes 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 4
- 206010010356 Congenital anomaly Diseases 0.000 claims description 4
- 206010062264 Congenital hyperthyroidism Diseases 0.000 claims description 4
- 206010010774 Constipation Diseases 0.000 claims description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 4
- 206010014561 Emphysema Diseases 0.000 claims description 4
- 208000024720 Fabry Disease Diseases 0.000 claims description 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 4
- 208000005139 Hereditary Angioedema Types I and II Diseases 0.000 claims description 4
- 208000033981 Hereditary haemochromatosis Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 4
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims description 4
- 208000000038 Hypoparathyroidism Diseases 0.000 claims description 4
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims description 4
- 208000019693 Lung disease Diseases 0.000 claims description 4
- 208000015439 Lysosomal storage disease Diseases 0.000 claims description 4
- 208000007466 Male Infertility Diseases 0.000 claims description 4
- 206010028289 Muscle atrophy Diseases 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 208000025966 Neurological disease Diseases 0.000 claims description 4
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims description 4
- 208000035467 Pancreatic insufficiency Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 4
- 108091000054 Prion Proteins 0.000 claims description 4
- 208000024777 Prion disease Diseases 0.000 claims description 4
- 201000005660 Protein C Deficiency Diseases 0.000 claims description 4
- 208000011641 Spinocerebellar disease Diseases 0.000 claims description 4
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims description 4
- 208000004622 abetalipoproteinemia Diseases 0.000 claims description 4
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 4
- 229960004099 azithromycin Drugs 0.000 claims description 4
- 230000002146 bilateral effect Effects 0.000 claims description 4
- 208000007451 chronic bronchitis Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims description 4
- 208000012770 hereditary angioedema type 1 Diseases 0.000 claims description 4
- 208000013746 hereditary thrombophilia due to congenital protein C deficiency Diseases 0.000 claims description 4
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 4
- 201000008980 hyperinsulinism Diseases 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 201000000585 muscular atrophy Diseases 0.000 claims description 4
- 208000000638 myeloperoxidase deficiency Diseases 0.000 claims description 4
- 230000003274 myotonic effect Effects 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 4
- 230000020978 protein processing Effects 0.000 claims description 4
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 claims description 4
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 claims description 4
- 201000000306 sarcoidosis Diseases 0.000 claims description 4
- 201000009890 sinusitis Diseases 0.000 claims description 4
- 230000000391 smoking effect Effects 0.000 claims description 4
- 229960003989 tocilizumab Drugs 0.000 claims description 4
- 210000001177 vas deferen Anatomy 0.000 claims description 4
- 208000008955 Mucolipidoses Diseases 0.000 claims description 3
- 206010072928 Mucolipidosis type II Diseases 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- XRGNABQSJLQUGV-UHFFFAOYSA-N bamaluzole Chemical compound N1=CC=C2N(C)C=NC2=C1OCC1=CC=CC=C1Cl XRGNABQSJLQUGV-UHFFFAOYSA-N 0.000 claims description 3
- 229950010457 bamaluzole Drugs 0.000 claims description 3
- 230000003176 fibrotic effect Effects 0.000 claims description 3
- 208000020460 mucolipidosis II alpha/beta Diseases 0.000 claims description 3
- 230000020763 muscle atrophy Effects 0.000 claims description 3
- LIFDPEORUVTOCP-UHFFFAOYSA-N saripidem Chemical compound N1=C2C=CC=CN2C(CN(C)C(=O)CCC)=C1C1=CC=C(Cl)C=C1 LIFDPEORUVTOCP-UHFFFAOYSA-N 0.000 claims description 3
- 229950007359 saripidem Drugs 0.000 claims description 3
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 229940112586 kaletra Drugs 0.000 claims description 2
- 229950006348 sarilumab Drugs 0.000 claims description 2
- 230000036428 airway hyperreactivity Effects 0.000 claims 2
- AURFZBICLPNKBZ-FZCSVUEKSA-N 3beta-hydroxy-5alpha-pregnan-20-one Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-FZCSVUEKSA-N 0.000 claims 1
- 206010052613 Allergic bronchitis Diseases 0.000 claims 1
- 201000002909 Aspergillosis Diseases 0.000 claims 1
- 208000036641 Aspergillus infections Diseases 0.000 claims 1
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 claims 1
- 102000008946 Fibrinogen Human genes 0.000 claims 1
- 108010049003 Fibrinogen Proteins 0.000 claims 1
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 1
- 206010020565 Hyperaemia Diseases 0.000 claims 1
- OFFWOVJBSQMVPI-RMLGOCCBSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O.N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 OFFWOVJBSQMVPI-RMLGOCCBSA-N 0.000 claims 1
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 claims 1
- 229940012952 fibrinogen Drugs 0.000 claims 1
- 229940120922 lopinavir and ritonavir Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 60
- 229920002401 polyacrylamide Polymers 0.000 description 152
- 150000003431 steroids Chemical class 0.000 description 69
- AURFZBICLPNKBZ-SYBPFIFISA-N brexanolone Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-SYBPFIFISA-N 0.000 description 53
- 238000012423 maintenance Methods 0.000 description 52
- 230000036470 plasma concentration Effects 0.000 description 34
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 28
- 238000012216 screening Methods 0.000 description 24
- 239000000203 mixture Substances 0.000 description 14
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 13
- 230000010085 airway hyperresponsiveness Effects 0.000 description 13
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 13
- 238000009423 ventilation Methods 0.000 description 12
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 11
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 10
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 230000004872 arterial blood pressure Effects 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 239000007909 solid dosage form Substances 0.000 description 9
- 208000001528 Coronaviridae Infections Diseases 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 8
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical class C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 7
- 102000014150 Interferons Human genes 0.000 description 7
- 108010050904 Interferons Proteins 0.000 description 7
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 230000001624 sedative effect Effects 0.000 description 7
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000036765 blood level Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000001934 delay Effects 0.000 description 6
- 238000002483 medication Methods 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 238000009597 pregnancy test Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000000932 sedative agent Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- WUBBRNOQWQTFEX-UHFFFAOYSA-M 4-aminosalicylate(1-) Chemical compound NC1=CC=C(C([O-])=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-M 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 5
- 206010050685 Cytokine storm Diseases 0.000 description 5
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 5
- 206010052015 cytokine release syndrome Diseases 0.000 description 5
- 229940114119 gentisate Drugs 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 5
- 229960004134 propofol Drugs 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 206010039897 Sedation Diseases 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229940072107 ascorbate Drugs 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 238000002695 general anesthesia Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- 150000004701 malic acid derivatives Chemical class 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000036387 respiratory rate Effects 0.000 description 4
- 230000036280 sedation Effects 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000002627 tracheal intubation Methods 0.000 description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 206010051125 Hypofibrinogenaemia Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 3
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Natural products C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 3
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 3
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- 229940124301 concurrent medication Drugs 0.000 description 3
- 238000013480 data collection Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000035487 diastolic blood pressure Effects 0.000 description 3
- 229940120124 dichloroacetate Drugs 0.000 description 3
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 229960004525 lopinavir Drugs 0.000 description 3
- 230000004199 lung function Effects 0.000 description 3
- 150000002690 malonic acid derivatives Chemical class 0.000 description 3
- 229960003793 midazolam Drugs 0.000 description 3
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 150000003891 oxalate salts Chemical class 0.000 description 3
- 238000002640 oxygen therapy Methods 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 201000004193 respiratory failure Diseases 0.000 description 3
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 3
- 229960000311 ritonavir Drugs 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 230000035488 systolic blood pressure Effects 0.000 description 3
- 229940095064 tartrate Drugs 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 208000007788 Acute Liver Failure Diseases 0.000 description 2
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 2
- 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 206010012218 Delirium Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 208000008771 Lymphadenopathy Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000034486 Multi-organ failure Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000013228 adenopathy Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 2
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 150000001860 citric acid derivatives Chemical class 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 229940109275 cyclamate Drugs 0.000 description 2
- JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical compound OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 208000028208 end stage renal disease Diseases 0.000 description 2
- 201000000523 end stage renal failure Diseases 0.000 description 2
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- 150000002688 maleic acid derivatives Chemical class 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 2
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 2
- 230000002988 nephrogenic effect Effects 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 description 2
- 229960000249 pregnenolone Drugs 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- KWMLJOLKUYYJFJ-GASJEMHNSA-N (2xi)-D-gluco-heptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C(O)=O KWMLJOLKUYYJFJ-GASJEMHNSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- KMBRJVMBQNMRDM-UHFFFAOYSA-N 1-hydroxybutane-1-sulfonic acid Chemical compound CCCC(O)S(O)(=O)=O KMBRJVMBQNMRDM-UHFFFAOYSA-N 0.000 description 1
- AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- MLMQPDHYNJCQAO-UHFFFAOYSA-N 3,3-dimethylbutyric acid Chemical compound CC(C)(C)CC(O)=O MLMQPDHYNJCQAO-UHFFFAOYSA-N 0.000 description 1
- OJDZHBWEGLIKRW-UHFFFAOYSA-N 3-[(4-hydroxyphenyl)methyl]benzoic acid Chemical compound OC(=O)C1=CC=CC(CC=2C=CC(O)=CC=2)=C1 OJDZHBWEGLIKRW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006473 Bronchopulmonary aspergillosis Diseases 0.000 description 1
- 208000029402 Bulbospinal muscular atrophy Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 238000008789 Direct Bilirubin Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 244000309467 Human Coronavirus Species 0.000 description 1
- 208000015178 Hurler syndrome Diseases 0.000 description 1
- 208000027747 Kennedy disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000004430 Pulmonary Aspergillosis Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940113720 aminosalicylate Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 229950009652 brexanolone Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003874 central nervous system depressant Substances 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethane-1,2-disulfonate Chemical compound [O-]S(=O)(=O)CCS([O-])(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 108010078430 glutamine phenylacetyltransferase Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000013003 healing agent Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002689 maleic acids Chemical class 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- XTEGVFVZDVNBPF-UHFFFAOYSA-L naphthalene-1,5-disulfonate(2-) Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1S([O-])(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-L 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (16)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062994805P | 2020-03-25 | 2020-03-25 | |
| US202062994803P | 2020-03-25 | 2020-03-25 | |
| US62/994,803 | 2020-03-25 | ||
| US62/994,805 | 2020-03-25 | ||
| US202063000418P | 2020-03-26 | 2020-03-26 | |
| US202063000415P | 2020-03-26 | 2020-03-26 | |
| US63/000,418 | 2020-03-26 | ||
| US63/000,415 | 2020-03-26 | ||
| US202063006672P | 2020-04-07 | 2020-04-07 | |
| US202063006671P | 2020-04-07 | 2020-04-07 | |
| US63/006,671 | 2020-04-07 | ||
| US63/006,672 | 2020-04-07 | ||
| US202063063803P | 2020-08-10 | 2020-08-10 | |
| US202063063780P | 2020-08-10 | 2020-08-10 | |
| US63/063,780 | 2020-08-10 | ||
| US63/063,803 | 2020-08-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202202146A true TW202202146A (zh) | 2022-01-16 |
Family
ID=75478347
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110110914A TW202202146A (zh) | 2020-03-25 | 2021-03-25 | 用於治療呼吸病況之ｇａｂａａ調節劑之用途 |
| TW110110915A TW202143977A (zh) | 2020-03-25 | 2021-03-25 | 用於治療呼吸病況之藥劑用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110110915A TW202143977A (zh) | 2020-03-25 | 2021-03-25 | 用於治療呼吸病況之藥劑用途 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20230346801A1 (https=) |
| EP (1) | EP4125921A1 (https=) |
| JP (1) | JP2023519241A (https=) |
| KR (1) | KR20220157426A (https=) |
| CN (1) | CN115551514A (https=) |
| AU (1) | AU2021241622A1 (https=) |
| BR (1) | BR112022019085A2 (https=) |
| CA (1) | CA3176854A1 (https=) |
| CL (1) | CL2022002592A1 (https=) |
| CO (1) | CO2022013777A2 (https=) |
| IL (1) | IL296645A (https=) |
| MX (1) | MX2022011804A (https=) |
| PE (1) | PE20221911A1 (https=) |
| TW (2) | TW202202146A (https=) |
| WO (2) | WO2021195301A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2806877B2 (en) | 2012-01-23 | 2025-01-29 | Sage Therapeutics, Inc. | Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin |
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| CN118027131A (zh) * | 2019-08-07 | 2024-05-14 | 上海翰森生物医药科技有限公司 | 一种甾族类衍生物调节剂的盐及其晶型 |
| WO2022067044A1 (en) * | 2020-09-25 | 2022-03-31 | The Regents Of The University Of California | Compositions and methods for ameliorating medical conditions |
| WO2022115381A1 (en) * | 2020-11-25 | 2022-06-02 | Sage Therapeutics, Onc. | Compositions and methods for treating cns disorders cross reference to related application |
| US20250170147A1 (en) * | 2022-02-28 | 2025-05-29 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
| EP4650359A1 (en) * | 2022-07-28 | 2025-11-19 | Hunan Kyf Pharmaceutical. Co., Ltd. | Steroid compound for treating central nervous system disease, method for preparing same, and use and pharmaceutical composition thereof |
| CN116999444B (zh) * | 2023-09-01 | 2026-03-20 | 山东中医药大学 | 四氢孕酮在制备抗流感病毒药物中的应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA73736C2 (en) | 1999-04-29 | 2005-09-15 | Euro Celtic S A | Method for alleviating or preventing insomnia and inducing anesthesia |
| US20030045449A1 (en) * | 2001-08-15 | 2003-03-06 | Pfizer, Inc. | Pharmaceutical combinations for the treatment of neurodegenerative diseases |
| EP3572417B1 (en) | 2011-10-14 | 2025-12-17 | Sage Therapeutics, LLC | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| EP2806877B2 (en) | 2012-01-23 | 2025-01-29 | Sage Therapeutics, Inc. | Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin |
| US20150175651A1 (en) | 2012-06-15 | 2015-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| AU2013352141B2 (en) | 2012-11-30 | 2018-04-05 | The Regents Of The University Of California | Anticonvulsant activity of steroids |
| HUE039057T2 (hu) | 2012-12-18 | 2018-12-28 | Univ Washington | Kezelési eljárásokban alkalmazható neuroaktív 19-alkoxi-17-szubsztituált szteroidok |
| EP2986624B1 (en) | 2013-04-17 | 2020-03-25 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids for methods of treatment |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
| KR102396328B1 (ko) * | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| SI3021852T1 (sl) | 2013-07-19 | 2021-07-30 | Sage Therapeutics, Inc. | Nevroaktivni steroidi, sestavki in uporabe le-teh |
| AU2014308621C1 (en) | 2013-08-23 | 2022-01-06 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2016036724A1 (en) * | 2014-09-02 | 2016-03-10 | The Texas A&M University System | Method of treating organophosphate intoxication |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| CN117024501A (zh) | 2014-10-16 | 2023-11-10 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| ME03809B (me) | 2014-10-16 | 2021-04-20 | Sage Therapeutics Inc | KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| RS61530B1 (sr) | 2015-01-26 | 2021-04-29 | Sage Therapeutics Inc | Kompozicije i postupci za lečenje poremećaja cns |
| EP4155314A1 (en) | 2015-02-20 | 2023-03-29 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| MA43284A (fr) | 2015-11-20 | 2018-09-26 | Sage Therapeutics Inc | Composés et leurs méthodes d'utilisation |
| KR20240157128A (ko) | 2016-03-08 | 2024-10-31 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드, 조성물, 및 그의 용도 |
| MA45599A (fr) | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| WO2018013615A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| WO2019051264A1 (en) | 2017-09-07 | 2019-03-14 | Sage Therapeutics, Inc. | NEUROACTIVE STEROIDS AND METHODS OF USE |
| US20200276209A1 (en) | 2017-09-11 | 2020-09-03 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| MX2020006599A (es) | 2017-12-22 | 2020-11-06 | Sage Therapeutics Inc | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. |
| TW201930269A (zh) | 2018-01-12 | 2019-08-01 | 美商賽吉醫療公司 | 用於治療cns病症之組合物及方法 |
| WO2019154257A1 (zh) | 2018-02-11 | 2019-08-15 | 江苏豪森药业集团有限公司 | 一种甾族类衍生物调节剂及其制备方法和应用 |
| WO2019226515A1 (en) * | 2018-05-21 | 2019-11-28 | The University Of North Carolina At Chapel Hill | Methods of inhibiting proinflammatory neuroimmune signaling and treating inflammatory disorders |
| CA3103421A1 (en) | 2018-06-12 | 2019-12-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| CN112888437A (zh) * | 2018-08-22 | 2021-06-01 | 奥维德医疗公司 | 加波沙朵在治疗胃肠道紊乱和哮喘中的用途 |
| US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| WO2020185710A1 (en) * | 2019-03-08 | 2020-09-17 | Alairion, Inc. | Method for treating sleep fragmentation disorders using neurosteroid positive allosteric modulators of the gabaa receptor |
-
2021
- 2021-03-24 EP EP21719408.3A patent/EP4125921A1/en not_active Withdrawn
- 2021-03-24 JP JP2022557755A patent/JP2023519241A/ja active Pending
- 2021-03-24 WO PCT/US2021/024014 patent/WO2021195301A1/en not_active Ceased
- 2021-03-24 WO PCT/US2021/024010 patent/WO2021195297A1/en not_active Ceased
- 2021-03-24 MX MX2022011804A patent/MX2022011804A/es unknown
- 2021-03-24 BR BR112022019085A patent/BR112022019085A2/pt unknown
- 2021-03-24 US US17/913,936 patent/US20230346801A1/en active Pending
- 2021-03-24 AU AU2021241622A patent/AU2021241622A1/en not_active Abandoned
- 2021-03-24 US US17/913,916 patent/US20230414636A1/en active Pending
- 2021-03-24 CA CA3176854A patent/CA3176854A1/en active Pending
- 2021-03-24 KR KR1020227035963A patent/KR20220157426A/ko active Pending
- 2021-03-24 CN CN202180034342.3A patent/CN115551514A/zh active Pending
- 2021-03-24 IL IL296645A patent/IL296645A/en unknown
- 2021-03-24 PE PE2022002100A patent/PE20221911A1/es unknown
- 2021-03-25 TW TW110110914A patent/TW202202146A/zh unknown
- 2021-03-25 TW TW110110915A patent/TW202143977A/zh unknown
-
2022
- 2022-09-23 CL CL2022002592A patent/CL2022002592A1/es unknown
- 2022-09-26 CO CONC2022/0013777A patent/CO2022013777A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20221911A1 (es) | 2022-12-23 |
| EP4125921A1 (en) | 2023-02-08 |
| KR20220157426A (ko) | 2022-11-29 |
| WO2021195297A1 (en) | 2021-09-30 |
| IL296645A (en) | 2022-11-01 |
| CA3176854A1 (en) | 2021-09-30 |
| CL2022002592A1 (es) | 2023-04-21 |
| BR112022019085A2 (pt) | 2023-01-31 |
| MX2022011804A (es) | 2023-03-09 |
| WO2021195301A1 (en) | 2021-09-30 |
| US20230346801A1 (en) | 2023-11-02 |
| TW202143977A (zh) | 2021-12-01 |
| US20230414636A1 (en) | 2023-12-28 |
| CO2022013777A2 (es) | 2022-10-11 |
| CN115551514A (zh) | 2022-12-30 |
| AU2021241622A1 (en) | 2022-10-20 |
| JP2023519241A (ja) | 2023-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202202146A (zh) | 用於治療呼吸病況之ｇａｂａａ調節劑之用途 | |
| Shang et al. | Mechanical ventilation in Guillain–Barré syndrome | |
| Iirola et al. | Bioavailability of dexmedetomidine after intranasal administration | |
| Gyanesh et al. | Comparison between intranasal dexmedetomidine and intranasal ketamine as premedication for procedural sedation in children undergoing MRI: a double-blind, randomized, placebo-controlled trial | |
| JP6858231B2 (ja) | ハンター症候群治療剤および治療方法 | |
| CN107073114A (zh) | 使用瑞利珠单抗治疗中度到重度嗜酸细胞性哮喘 | |
| Kaye et al. | Pharmacologic considerations of anesthetic agents in pediatric patients: a comprehensive review | |
| US20260021038A1 (en) | Compositions and Methods for the Treatment of Opioid Overdose | |
| EP3678643B1 (en) | Sublingual epinephrine tablets | |
| Wang et al. | Comparison of the ED50 of ciprofol combined with or without fentanyl for laryngeal mask airway insertion in children: a prospective, randomized, open-label, dose-response trial | |
| Mikuni et al. | Effects of changing from sevoflurane to desflurane on the recovery profile after sevoflurane induction: a randomized controlled study | |
| EP3393517B1 (en) | Acetylsalicylic acid for use in the treatment of moderate to severe influenza | |
| Liu et al. | Study protocol of a multicenter, randomized, single-blind trial: efficacy and safety of Remimazolam tosylate for sedation in ICU patients | |
| Sitilci et al. | Comparison of patients with and without intellectual disability under general anesthesia: A retrospective study | |
| US20230285350A1 (en) | Formulations for tetracaine and lidocaine | |
| Simić et al. | The importance of preoperative preparation of pediatric patients | |
| WO2021225974A1 (en) | Epinephrine pharmaceutical formulations for intranasal delivery | |
| US20230190697A1 (en) | Methods for treating viral infections with nafamostat | |
| JP2023525019A (ja) | 薬剤の経鼻送達のための促進剤としての胆汁酸及びその塩の安全な使用 | |
| WO2024251110A1 (en) | Induction of general anesthesia in adults undergoing elective surgery | |
| Tao et al. | Pharmacokinetics, Pharmacodynamics, and Safety of Ciprofol Injectable in Chinese Subjects with Normal or Impaired Renal Function | |
| TW201121540A (en) | Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom | |
| Jimin et al. | Effects of remimazolam combined with sufentanil on hemodynamics during anesthetic induction in advanced-age patients with hypertension undergoing orthopedic surgery of the lower limbs: a randomized, controlled trial | |
| Yan et al. | The minimum effective dose (MED90) of remimazolam for inhibiting responses to the insertion of a duodenoscope during ERCP | |
| Hiremath | Anaesthetic management of patient with Gilbert's syndrome |